Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.
The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.
This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.
Heather Perez Saiz, MA, LCSW, CCTSW, is the Independent Living Donor Advocate at Inova Fairfax…
Palak Shah, MD, MS Fairfax, VA — A research team at Inova Schar Heart and…
Jason Bonomo, MD, PhD, is a cardiologist at Inova Schar Heart and Vascular. Dr. Bonomo…
Update as of April 24, 2024: Inova’s structural heart team has now completed the first…
The Peterson Family Fairfax, VA, April 16, 2024 – Inova today announced a transformational gift…
Lauren Trahan, MS, RD is a Registered Dietitian. She serves patients in Inova Cardiac and…